The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Open accessAbstract
Risk-based treatment approaches for neuroblastoma have been ongoing for decades. However, the criteria used to define risk in various institutional and cooperative groups were disparate, limiting the ability to compare clinical trial results. To mitigate this problem and enhance collaborative research, homogenous pretreatment patient cohorts have been defined by the International Neuroblastoma Risk Group classification system. During the past 30 years, increasingly intensive, multimodality approaches have been developed to treat patients who are classified as high risk, whereas patients with low- or intermediate-risk neuroblastoma have received reduced therapy. This treatment approach has resulted in improved outcome, although survival for high-risk patients remains poor, emphasizing the need for more effective treatments. Increased knowledge regarding the biology and genetic basis of neuroblastoma has led to the discovery of druggable targets and promising, new therapeutic approaches. Collaborative efforts of institutions and international cooperative groups have led to advances in our understanding of neuroblastoma biology, refinements in risk classification, and stratified treatment strategies, resulting in improved outcome. International collaboration will be even more critical when evaluating therapies designed to treat small cohorts of patients with rare actionable mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Self-citationAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Self-citationIdentification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150
Self-citationThe International Neuroblastoma Pathology Classification (the Shimada system)
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7 · Cited by 1,067
Self-citationMatthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858
Self-citationMossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Lovejoy, C. A., Li, W., Reisenweber, S., Thongthip, S., Bruno, J., de Lange, T., De, S., Petrini, J. H. J., Sung, P. A., Jasin, M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002772 · Cited by 629
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Self-citationBrisse, H. J., McCarville, M. B., Granata, C., Krug, K. B., Wootton-Gorges, S. L., Kanegawa, K., Giammarile, F., Schmidt, M., Shulkin, B. L., Matthay, K. K., et al. (2011) · Radiology · doi:10.1148/radiol.11101352 · Cited by 520
Self-citationAssociation of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Cheung, N.-K. V. (2012) · JAMA · doi:10.1001/jama.2012.228 · Cited by 468
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Kochenderfer, J. N., & Rosenberg, S. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 451
Ambros, P. F., Ambros, I. M., Brodeur, G. M., Haber, M., Khan, J., Nakagawara, A., Schleiermacher, G., Speleman, F., Spitz, R., London, W. B., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605014 · Cited by 404
Self-citationBerthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70291-6 · Cited by 402
Self-citationHero, B., Simon, T., Spitz, R., Ernestus, K., Gnekow, A. K., Scheel-Walter, H.-G., Schwabe, D., Schilling, F. H., Benz-Bohm, G., & Berthold, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3349 · Cited by 311
Self-citationKreissman, S. G., Seeger, R. C., Matthay, K. K., London, W. B., Sposto, R., Grupp, S. A., Haas-Kogan, D. A., LaQuaglia, M. P., Yu, A. L., Diller, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70309-7 · Cited by 304
Self-citationBrockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H. E., Rycak, L., Jamin, Y., Thway, K., Robinson, S. P., Roels, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.005 · Cited by 299
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Asgharzadeh, S., Salo, J. A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C. W.-Y., Metelitsa, L. S., Pique-Regi, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9169 · Cited by 285
Self-citationGermline PHOX2B Mutation in Hereditary Neuroblastoma
Mosse, Y. P., Laudenslager, M., Khazi, D., Carlisle, A. J., Winter, C. L., Rappaport, E., & Maris, J. M. (2004) · The American Journal of Human Genetics · doi:10.1086/424530 · Cited by 284
Carén, H., Abel, F., Kogner, P., & Martinsson, T. (2008) · Biochemical Journal · doi:10.1042/bj20081834 · Cited by 280
Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8861 · Cited by 248
Self-citationDifferential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Bresler, S. C., Wood, A. C., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K., Toporovskaya, Y., Zhao, H., Carpenter, E. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002950 · Cited by 237
Strother, D. R., London, W. B., Schmidt, M. L., Brodeur, G. M., Shimada, H., Thorner, P., Collins, M. H., Tagge, E., Adkins, S., Reynolds, C. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9990 · Cited by 234
Self-citationFunctional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification
Valentijn, L. J., Koster, J., Haneveld, F., Aissa, R. A., van Sluis, P., Broekmans, M. E. C., Molenaar, J. J., van Nes, J., & Versteeg, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208215109 · Cited by 228
Matthay, K. K., Shulkin, B., Ladenstein, R., Michon, J., Giammarile, F., Lewington, V, Pearson, A. D. J., & Cohn, S. L. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605621 · Cited by 225
Self-citationEmergence of New ALK Mutations at Relapse of Neuroblastoma
Schleiermacher, G., Javanmardi, N., Bernard, V., Leroy, Q., Cappo, J., Rio Frio, T., Pierron, G., Lapouble, E., Combaret, V., Speleman, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0674 · Cited by 215
Self-citationGeorge, R. E., Li, S., Medeiros-Nancarrow, C., Neuberg, D., Marcus, K., Shamberger, R. C., Pulsipher, M., Grupp, S. A., & Diller, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6986 · Cited by 205
Chesler, L., Schlieve, C., Goldenberg, D. D., Kenney, A., Kim, G., McMillan, A., Matthay, K. K., Rowitch, D., & Weiss, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2769 · Cited by 202
Self-citationNuchtern, J. G., London, W. B., Barnewolt, C. E., Naranjo, A., McGrady, P. W., Geiger, J. D., Diller, L., Schmidt, M. L., Maris, J. M., Cohn, S. L., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826cbbbd · Cited by 200
Self-citationVermeulen, J., De Preter, K., Naranjo, A., Vercruysse, L., Van Roy, N., Hellemans, J., Swerts, K., Bravo, S., Scaruffi, P., Tonini, G. P., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70154-8 · Cited by 192
Self-citationPritchard, J., Cotterill, S. J., Germond, S. M., Imeson, J., de Kraker, J., & Jones, D. R. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20219 · Cited by 183
177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma
Gains, J. E., Bomanji, J. B., Fersht, N. L., Sullivan, T., D'Souza, D., Sullivan, K. P., Aldridge, M., Waddington, W., & Gaze, M. N. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.085100 · Cited by 170
Navid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4423 · Cited by 165
A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma
Wilson, J. S., Gains, J. E., Moroz, V., Wheatley, K., & Gaze, M. N. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.016 · Cited by 161
Henderson, T. O., Bhatia, R., Pinto, N. R., London, W. B., McGrady, P., Crotty, C., Sun, C., & Cohn, S. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6103 · Cited by 154
Self-citationKushner, B. H., Cheung, I. Y., Modak, S. I., Kramer, K., Ragupathi, G., & Cheung, N. V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1012 · Cited by 147
Yalçın, B., Kremer, L. C. M., & van Dalen, E. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006301.pub4 · Cited by 141
Bernardi, B. D., Gerrard, M., Boni, L., Rubie, H., Cañete, A., Cataldo, A. D., Castel, V., Lacerda, A., Ladenstein, R. L., Ruud, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5877 · Cited by 141
Self-citationPrognostic Impact of Gene Expression–Based Classification for Neuroblastoma
Oberthuer, A., Hero, B., Berthold, F., Juraeva, D., Faldum, A., Kahlert, Y., Asgharzadeh, S., Seeger, R., Scaruffi, P., Tonini, G. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3367 · Cited by 135
Self-citationBernardi, B. D., Mosseri, V., Rubie, H., Castel, V., Foot, A. B. M., Ladenstein, R. L., Laureys, G., Popovic, M. B., Lacerda, A., Pearson, A. D. J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604640 · Cited by 132
Self-citationRare Variants in TP53 and Susceptibility to Neuroblastoma
Diskin, S. J., Capasso, M., Diamond, M. A., Oldridge, D. A., Conkrite, K. L., Bosse, K. R., Russell, M. R., Iolascon, A., Hakonarson, H. H., Devoto, M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju047 · Cited by 118
Capasso, M., Diskin, S. J., Totaro, F., Longo, L., Mariano, M. D., Russo, R., Cimmino, F., Hakonarson, H. H., Tonini, G. P., Devoto, M., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs380 · Cited by 115
Hartmann, O., Valteau‐Couanet, D., Vassal, G., et al. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701737 · Cited by 110
Self-citationOberthuer, A., Juraeva, D., Hero, B., Volland, R., Sterz, C., Schmidt, R., Faldum, A., Kahlert, Y., Engesser, A., Asgharzadeh, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0817 · Cited by 106
Self-citationFardin, P., Barla, A., Mosci, S., Rosasco, L., Verri, A., Versteeg, R., Caron, H. N., Molenaar, J. J., Øra, I., Eva, A., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-185 · Cited by 103
Accurate prediction of neuroblastoma outcome based on miRNA expression profiles
Schulte, J. H., Schowe, B., Mestdagh, P., Kaderali, L., Kalaghatgi, P., Schlierf, S., Vermeulen, J., Brockmeyer, B., Pajtler, K. W., Thor, T., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25436 · Cited by 100
Schleiermacher, G., Michon, J. M., Ribeiro, A., Pierron, G., Mosseri, V., Rubie, H., Munzer, C., Bénard, J., Auger, N., Combaret, V., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.472 · Cited by 99
Self-citationDecock, A., Ongenaert, M., Hoebeeck, J., Preter, K. D., Peer, G. V., Criekinge, W. V., Ladenstein, R. L., Schulte, J. H., Noguera, R., Stallings, R., et al. (2012) · Genome biology · doi:10.1186/gb-2012-13-10-r95 · Cited by 83
DuBois, S. G., Chesler, L., Groshen, S. G., Hawkins, R. A., Goodarzian, F., Shimada, H., Yanik, G. A., Tagen, M., Stewart, C., Mossé, Y. P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3201 · Cited by 74
Self-citationMatthay, K. K., Weiss, B., Villablanca, J. G., Maris, J. M., Yanik, G. A., DuBois, S. G., Stubbs, J., Groshen, S., Tsao-Wei, D., Hawkins, R., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098624 · Cited by 67
Self-citationHong, H., Stastny, M. J., Brown, C. E., Chang, W.-C., Ostberg, J. R., Forman, S. J., & Jensen, M. C. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000018 · Cited by 67
A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma
García, I., Mayol, G., Ríos, J., Doménech, G., Cheung, N. V., Oberthuer, A., Fischer, M., Maris, J. M., Brodeur, G. M., Hero, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2483 · Cited by 67
Yalçın, B., Kremer, L. C. M., Caron, H. N., & van Dalen, E. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006301.pub3 · Cited by 49
Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma
Krishnadas, D. K., Shapiro, T., & Lucas, K. G. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0376 · Cited by 46
Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival
Gamazon, E. R., Pinto, N. R., Konkashbaev, A. I., Im, H. K., Diskin, S. J., London, W. B., Maris, J. M., Dolan, M. E., Cox, N. J., & Cohn, S. L. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs503 · Cited by 41
Self-citationAllogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience
Hale, G. A., Arora, M., Ahn, K. W., He, W., Camitta, B. M., Bishop, M. R., Bitan, M., Cairo, M. S., Chan, K. W., Childs, R. W., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.284 · Cited by 37
Cited by
Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Self-citationRevised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
Irwin, M. S., Naranjo, A., Zhang, F. F., Cohn, S. L., London, W. B., Gastier-Foster, J. M., Ramirez, N. C., Pfau, R., Reshmi, S., Wagner, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00278 · Cited by 494
Self-citationMolecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
Park, J. R., Bagatell, R., Cohn, S. L., Pearson, A. D., Villablanca, J. G., Berthold, F., Burchill, S., Boubaker, A., McHugh, K., Nuchtern, J. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.0177 · Cited by 365
Self-citationPark, J. R., Kreissman, S. G., London, W. B., Naranjo, A., Cohn, S. L., Hogarty, M. D., Tenney, S. C., Haas-Kogan, D., Shaw, P. J., Kraveka, J. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.11642 · Cited by 358
Self-citation
Metadata
- Authors
- Pinto, N. R., Applebaum, M. A., Volchenboum, S. L., Matthay, K. K., London, W. B., Ambros, P. F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J. R., Valteau-Couanet, D., Pearson, A. D. J., & Cohn, S. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-09-20
- Volume
- 33
- Issue
- 27
- Pages
- 3008-3017
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097120541
- Cited by
- 911
- References
- 60
- FWCI
- 31.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.